Randomized Clinical Trial of Endovascular Treatment for Progressive Stroke With Vertebrobasilar Artery Occlusion
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFeng Gao
About this trial
This multicenter, prospective, open-label randomized controlled trial with blinded assessment was designed to assess the efficacy and safety of endovascular treatment for progressive stroke due to vertebrobasilar artery occlusion.
Eligibility criteria
Qualifiers
Age ≥18 years.
Acute ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of <10 at initial symptom onset, and no prior endovascular treatment.
Stroke progression occurring from 24 hours to 14 days after initial symptom onset, defined as an NIHSS score of ≥10 with an increase of ≥4 points from baseline.
Acute basilar artery occlusion or dominant vertebral artery occlusion with contralateral occlusion or hypoplasia, confirmed by CTA, MRA or DSA.
Disqualifiers
Any sign of intracranial hemorrhage (except microbleeds) on baseline brain imaging.
Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes.
Extensive cerebellar infarction with significant mass effect or bilateral thalamic infarction on baseline neuroimaging.
Presence of untreated intracranial aneurysm, intracranial tumor (except small meningioma and aneurysms <3 mm in diameter), or intracranial arteriovenous malformation.
Trial design
Treatments tested in this trial
- Endovascular Recanalization
- Medical Therapy Alone
Treatment groups
240 Participants
are divided into 2 treatment groupsSponsors and collaborators
Feng Gao
Lead sponsor
Beijing Tiantan Hospital
Sponsor institution
Source ClinicalTrials.gov